نتایج جستجو برای: pharmaceutical products

تعداد نتایج: 346359  

Journal: :World journal of pediatrics : WJP 2011
Yan-Ren Lin Tung-Kung Wu Tzu-An Liu Chu-Chung Chou Han-Ping Wu

BACKGROUND This paper reports the characteristics, outcomes and clinical features of children with poisoning treated at an emergency department (ED). METHODS This retrospective study at an emergency department consisted of 140 children with poison exposure who were aged under 18 years. Their characteristics were analyzed in order to understand the differences between accidental and non-accide...

2012
Wolfgang Boecking Anna Klamar Florian Kitzmann Wilhelm Kirch

BACKGROUND Most European health care systems are suffering from the impact of demographic change. In short, aging of society is leading to higher costs of treatment per capita, while reproduction rates below 2.1 children per woman lead to a reduced number of younger people to provide for the necessary contributions into the health insurance system.This research paper addresses the questions wha...

2001
Ron Pilchik

www.pharmaporta l .com ackaging is one of the largest industry sectors in the world, worth $280 billion. Consumer healthcare packaging represents 4% ($11.2 billion) of the packaging industry. As drug manufacturers approach the 21st century, they face a number of challenges that packaging can help them meet. A decade ago packaging often was an afterthought for many pharmaceutical companies, view...

Journal: :Clinical pharmacology and therapeutics 2011
C Gassmann-Mayer K Jiang P McSorley R Arani S Dubrava S Suryawanshi D M Webb M Nilsson

In the past two decades, the potential association between the risk of suicidal ideation and behavior and the clinical use of pharmaceutical products has been debated among industry, regulators, and academia. A better understanding of the possible effects-favorable, unfavorable, or neutral-of pharmaceuticals on the risk of suicidal ideation and behavior may be required, especially for trials ty...

Journal: :Revista peruana de medicina experimental y salud publica 2012
Hans Vásquez Sofía Salas Linder Figueroa Sonia Gutiérrez

Internationally, pharmaceutical products (FP) are authorized after their risk-benefit profile has been assessed, taking into account efficacy, safety and quality parameters. In 2009, it was established in Peru that all pharmaceutical products to be commercialized should show proof of their efficacy and safety. According to the new regulation, in effect as of 2012, the pharmaceutical specialties...

2015
Randy Chi Fai Cheung Tzi Bun Ng Jack Ho Wong Kellie L. Tuck

Peptides are important bioactive natural products which are present in many marine species. These marine peptides have high potential nutraceutical and medicinal values because of their broad spectra of bioactivities. Their antimicrobial, antiviral, antitumor, antioxidative, cardioprotective (antihypertensive, antiatherosclerotic and anticoagulant), immunomodulatory, analgesic, anxiolytic anti-...

Journal: :Journal of chromatographic science 2013
Eric Deconinck Pierre-Yves Sacré Patricia Courselle Jacques O De Beer

Counterfeit and illegal pharmaceutical products are an increasing worldwide problem and constitute a major challenge for analytical laboratories to detect and characterize them. Spectroscopic techniques such as infrared spectroscopy and Raman spectroscopy have always been the first methods of choice to detect counterfeits and illegal preparations, but due to the evolution in the seized products...

Journal: :Science 2000
M R Reich

Global inequities in access to pharmaceutical products exist between rich and poor countries because of market and government failures as well as huge income differences. Multiple policies are required to address this global drug gap for three categories of pharmaceutical products: essential drugs, new drugs, and yet-to-be-developed drugs. Policies should combine "push" approaches of subsidies ...

Journal: :Drug discovery today 2012
Ish Khanna

Low productivity, rising R&D costs, dissipating proprietary products and dwindling pipelines are driving the pharmaceutical industry to unprecedented challenges and scrutiny. In this article I reflect on the current status of the pharmaceutical industry and reasons for continued low productivity. An emerging 'symbiotic model of innovation', that addresses underlying issues in drug failure and a...

Journal: :Environmental Health Perspectives 2002
Ranga Velagaleti Philip K Burns Michael Gill James Prothro

The current Good Manufacturing Practice (cGMP) and effluent emission (use and disposal) regulations of the U.S. Food and Drug Administration (FDA) and manufacturing effluent discharge and emission regulations of the U.S. Environmental Protection Agency (U.S. EPA) require contained manufacture, use, and disposal of pharmaceuticals with the goal of minimizing the release of pharmaceutical chemica...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید